Patents Assigned to Graybug Vision, Inc.
-
Publication number: 20240092745Abstract: The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.Type: ApplicationFiled: January 9, 2023Publication date: March 21, 2024Applicant: Graybug Vision, Inc.Inventors: Ming Yang, John G. Bauman, Jeffrey L. Cleland, Nu Hoang, Emmett Cunningham
-
Publication number: 20240041783Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.Type: ApplicationFiled: January 27, 2023Publication date: February 8, 2024Applicant: Graybug Vision, Inc.Inventors: Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
-
Publication number: 20230056284Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.Type: ApplicationFiled: November 18, 2021Publication date: February 23, 2023Applicant: Graybug Vision, Inc.Inventors: Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
-
Publication number: 20230058971Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.Type: ApplicationFiled: November 18, 2021Publication date: February 23, 2023Applicant: Graybug Vision, Inc.Inventors: Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
-
Patent number: 11564890Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.Type: GrantFiled: September 10, 2019Date of Patent: January 31, 2023Assignee: Graybug Vision, Inc.Inventors: Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
-
Patent number: 11548861Abstract: The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.Type: GrantFiled: September 20, 2019Date of Patent: January 10, 2023Assignee: Graybug Vision, Inc.Inventors: Ming Yang, John G. Bauman, Jeffrey L. Cleland, Nu Hoang, Emmett Cunningham
-
Publication number: 20220402964Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.Type: ApplicationFiled: August 8, 2022Publication date: December 22, 2022Applicant: Graybug Vision, Inc.Inventors: Hans-Gottfried Genieser, Frank SCHWEDE, Andreas RENTSCH, Per EKSTRÖM, Valeria MARIGO, Francois PAQUET-DURAND
-
Patent number: 11407781Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.Type: GrantFiled: June 29, 2017Date of Patent: August 9, 2022Assignee: Graybug Vision, Inc.Inventors: Hans-Gottfried Genieser, Frank Schwede, Andreas Rentsch, Per Ekström, Valeria Marigo, Francois Paquet-Durand
-
Patent number: 11331276Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.Type: GrantFiled: September 10, 2019Date of Patent: May 17, 2022Assignee: Graybug Vision, Inc.Inventors: Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
-
Patent number: 11160870Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.Type: GrantFiled: May 10, 2018Date of Patent: November 2, 2021Assignee: Graybug Vision, Inc.Inventors: Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
-
Publication number: 20210275456Abstract: Compositions and methods are provided that include aggregating microparticles which include an active agent that exhibit an increased hardness and/or durability of the resulting aggregated microparticles in vivo, which can lead to more stable, long-term ocular therapy.Type: ApplicationFiled: May 13, 2021Publication date: September 9, 2021Applicant: Graybug Vision, Inc.Inventors: Ming Yang, Daniel Louis Salain, Charles Pauling Semba, Yun Yu, Weiling Yu, Joshua Kays, Jane Chisholm, Qingyun Lu, Jeffrey L. Cleland
-
Publication number: 20210214374Abstract: The present invention provides new prodrugs of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.Type: ApplicationFiled: March 25, 2021Publication date: July 15, 2021Applicant: Graybug Vision, Inc.Inventors: John G. Bauman, Ming Yang, Nu Hoang, Emmett Cunningham, Jeffrey L. Cleland
-
Publication number: 20210085607Abstract: The present invention is in the field of manufacturing drug-loaded microparticles, and specifically provides processes for producing approximately homogenously sized drug loaded microparticles with high drug loading and reproducible drug release profiles, and which may be provided in a significantly reduced time period.Type: ApplicationFiled: October 22, 2020Publication date: March 25, 2021Applicant: Graybug Vision, Inc.Inventors: Daniel Saragnese, Ming Yang, Yun Yu, Toni-Rose Guiriba, David McKenzie
-
Publication number: 20210040111Abstract: The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.Type: ApplicationFiled: October 22, 2020Publication date: February 11, 2021Applicant: Graybug Vision, Inc.Inventors: Ming Yang, John G. Bauman, Jinzhong Zhang, Nu Hoang, Jeffrey L. Cleland
-
Publication number: 20200308162Abstract: New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a microparticle in vivo, wherein the timolol prodrug containing microparticle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.Type: ApplicationFiled: June 11, 2020Publication date: October 1, 2020Applicant: Graybug Vision, Inc.Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Jane Chisholm
-
Publication number: 20200230246Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.Type: ApplicationFiled: March 17, 2020Publication date: July 23, 2020Applicant: Graybug Vision, Inc.Inventors: Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
-
Publication number: 20200031783Abstract: The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.Type: ApplicationFiled: September 20, 2019Publication date: January 30, 2020Applicant: Graybug Vision, Inc.Inventors: Ming Yang, John G. Bauman, Jeffrey L. Cleland
-
Patent number: 10485876Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.Type: GrantFiled: October 16, 2018Date of Patent: November 26, 2019Assignee: Graybug Vision, Inc.Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
-
Patent number: 10441548Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.Type: GrantFiled: November 11, 2016Date of Patent: October 15, 2019Assignee: Graybug Vision, Inc.Inventors: Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
-
Publication number: 20190060474Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.Type: ApplicationFiled: October 16, 2018Publication date: February 28, 2019Applicant: Graybug Vision, Inc.Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham